The FDA on April 15, 2020 approved JELMYTO® for adult patients with low-grade upper tract urothelial cancer. JELMYTO® is a product of UroGen Pharma.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement
Leaving ChemoPrescribe
You are now leaving ChemoPrescribe website.
To return to the website, click on the back arrow on your browser.